^
    Back
    Association details:
    Biomarker:RET rearrangement
    Cancer:Non Small Cell Lung Cancer
    Drug:Cabometyx (cabozantinib tablet) (Multi-tyrosine kinase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    09/15/2020
    Excerpt:
    The Panel recommends selpercatinib, pralsetinib, cabozantinib, or vandetanib (category 2B for vandetanib) as subsequent therapy options for select patients with RET rearrangement positive metastatic NSCLC who have not previously received these agents…
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrialsregister.eu
    Title:

    Phase II study with Cabozantinib in patients with RET positive NSCLC Studio di fase II con Cabozantinib in pazienti con NSCLC RET positivo

    Excerpt:
    ...RET gene rearrangement by local laboratory analysis with an approved standard method (FISH or Next Generation Sequencing Panel). ...
    Trial ID:
    2018-002948-88
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Phase II Study With Cabozantinib in Patients With RET Positive NSCLC

    Excerpt:
    ...RET gene rearrangement by local laboratory analysis with an approved standard method (FISH or Next Generation Sequencing Panel)....
    Trial ID:
    CRETA